Drugs / ISIS 2503
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00006467 | Feb 2001 → Jan 2004 | pancreatic adenocarcinoma | Alliance for Clinical Trials in Oncology | Completed | Met primary |
| Phase 2 | NCT00005594 | Jul → Dec 2000 | malignant pancreatic neoplasm | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT00004193 | Jan 1999 → Nov 2000 | colorectal cancer | University of Alabama at Birmingham | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2003-06-03 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Provides Summary of American Society of Clinical Oncology Data Presentations on Anti-Cancer Antisense Drugs in Development ionis.com ↗
Also presented were final results from two Phase II studies of ISIS 2503, an antisense agent targeting Ha-ras, in combination with chemotherapy in patients with pancreatic and breast cancers. |
| 2002-12-18 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports New Data From Phase II Clinical Trial Of ISIS 2503 Plus Chemotherapy in Pancreatic Cancer ionis.com ↗
In a Phase II clinical trial of ISIS 2503 in combination with gemcitabine, median survival time was more than six months in patients with pancreatic cancer, exceeding the primary endpoint of the study. |
| 2002-04-10 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Preliminary Phase II Data On ISIS 2503 Plus Chemotherapy in Pancreatic Cancer ionis.com ↗
In a planned interim analysis of a Phase II trial of the antisense anti-cancer compound ISIS 2503 in combination with gemcitabine, clinical investigators observed six months or longer survival in patients with pancreatic cancer, surpassing the primary endpoint of the study's defined criteria for success. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2003-06-03 | Ionis Pharmaceuticals | Isis Pharmaceuticals Provides Summary of American Society of Clinical Oncology Data Presentations on Anti-Cancer Antisense Drugs in Development ionis.com ↗ |
| 2002-12-18 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports New Data From Phase II Clinical Trial Of ISIS 2503 Plus Chemotherapy in Pancreatic Cancer ionis.com ↗ |
| 2002-04-10 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports Preliminary Phase II Data On ISIS 2503 Plus Chemotherapy in Pancreatic Cancer ionis.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS-2503 | “ISIS-2503 is an antisense compound directed against H-ras with preclinical activity against pancreatic ACA in tumor models.” PMID 15611509 ↗ Dec 2004 |
| Action | Inhibit | “ISIS 2503, an antisense inhibitor of H-ras” NCT00004193 ↗ |
| Modality | Antisense oligonucleotide | “ISIS 2503, an antisense inhibitor of H-ras” NCT00004193 ↗ |
| Route | Intravenous | “Patients receive ISIS 2503 IV continuously for 14 days.” NCT00004193 ↗ |
| Target | HRAS | “ISIS 2503, an antisense inhibitor of H-ras” NCT00004193 ↗ |